Actualités de la communauté
20.10.2017 Abionic Announces FDA Registration for World’s Most Rapid Allergy Test and abioSCOPE® Diagnostic Testing Platform
LAUSANNE, Switzerland–(BUSINESS WIRE)–Abionic SA, a developer of disrupter nanotechnology based rapid diagnostic solutions, announced today that its rapid allergy test, IVD CAPSULE Aeroallergens, and the easy to use testing platform, abioSCOPE® have been registered in the United States by the Food and Drug Administration (FDA). Abionic intends to commence commercialization of IVD CAPSULE Aeroallergens in this market in 2018.
Press release available here